Opus Genetics (IRD) said Friday that it has priced a $20 million underwritten public offering, as well as a concurrent private placement for gross proceeds of $1.5 million.
The ophthalmic biotechnology company said there will also be up to $21.4 million in additional proceeds when the warrants are exercised. The offerings are expected to close Monday.
Opus said the net proceeds will be used to fund the clinical development of its lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, as well as general corporate purposes and working capital.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。